| Trial ID: | L1253 |
| Source ID: | NCT00270478
|
| Associated Drug: |
Erythropoietin And Hydroxyurea
|
| Title: |
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Sickle Cell Disease|Chronic Kidney Disease|Pulmonary Hypertension
|
| Interventions: |
DRUG: Erythropoietin and Hydroxyurea
|
| Outcome Measures: |
Primary: An increase in fetal hemoglobin, as measured by high performance liquid chromatograph, from hydroxyurea alone/stabilized baseline to concurrent Erythropoietin in standard therapy/sequence l. | Secondary: (All measured, at a minimum, at study entry, at change of dose, and with stabilization at the conclusion of each Erythropoietin sequence, standard or cycled).
|
| Sponsor/Collaborators: |
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
7
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT
|
| Start Date: |
2005-12-21
|
| Completion Date: |
2009-08-31
|
| Results First Posted: |
|
| Last Update Posted: |
2019-12-17
|
| Locations: |
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00270478
|
